Literature DB >> 7441522

Sites of antinociceptive action of systemically injected morphine: involvement of supraspinal loci as revealed by intracerebroventricular injection of naloxone.

J C Yeung, T A Rudy.   

Abstract

Dose-response lines for the tail-flick and hot plate tests were obtained in rats which had received systemic injections of morphine (10-150 mg/kg i.p.) and intracerebroventricular (i.v.t.) injections of naloxone (3-20 micrograms). Diffusion studies indicated that the antagonist remained localized within supraspinal structures. Between the doses of 3 and 10 micrograms i.v.t. naloxone produced a dose-dependent rightward shifting of the morphine dose-response lines, the shift produced by the 10-micrograms dose being sufficient to abolish the analgetic action of morphine doses as large as 75 mg/kg. Higher doses of naloxone (e.g., 20 micrograms) produced no additional rightward shift, indicating an inability of i.v.t. naloxone to antagonize the analgesia produced by high systemic doses of morphine. These findings seem to suggest that analgesia produced by low to moderate systemic doses of morphine is mediated entirely by an action of the narcotic upon supraspinal structures. However, the results of an analogous study in which naloxone was injected into the spinal subarachnoid space indicated that analgesia produced by morphine given systemically in low to moderate doses is mediated exclusively by an action on the spinal cord. This apparent paradox can be resolved if one assumes that the total analgesia observed after a low to moderate systemic dose of morphine is a result of a multiplicative, rather than an additive, interaction of narcotic agonisms expressed at the spinal and supraspinal sites of action, respectively.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7441522

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Differential analgesic effects of a mu-opioid peptide, [Dmt(1)]DALDA, and morphine.

Authors:  Megumi Shimoyama; Hazel H Szeto; Peter W Schiller; Yugo Tagaito; Hideyuki Tokairin; Chong moon Eun; Naohito Shimoyama
Journal:  Pharmacology       Date:  2008-11-06       Impact factor: 2.547

2.  Entanglement between thermoregulation and nociception in the rat: the case of morphine.

Authors:  Nabil El Bitar; Bernard Pollin; Elias Karroum; Ivanne Pincedé; Daniel Le Bars
Journal:  J Neurophysiol       Date:  2016-09-07       Impact factor: 2.714

3.  CC12, a P450/epoxygenase inhibitor, acts in the rat rostral, ventromedial medulla to attenuate morphine antinociception.

Authors:  Jennie L Conroy; Julia W Nalwalk; James G Phillips; Lindsay B Hough
Journal:  Brain Res       Date:  2013-01-05       Impact factor: 3.252

4.  Postoperative analgesia with minidose intrathecal morphine for bipolar hip prosthesis in extremely elderly patients.

Authors:  Kazunori Yamashita; Makoto Fukusaki; Yuko Ando; Takahiro Tanabe; Yoshiaki Terao; Koji Sumikawa
Journal:  J Anesth       Date:  2009-11-18       Impact factor: 2.078

5.  Epidural morphine reduces halothane MAC in humans.

Authors:  I M Schwieger; C E Klopfenstein; A Forster
Journal:  Can J Anaesth       Date:  1992-11       Impact factor: 5.063

6.  Memantine and dizocilpine interactions with antinociceptive or discriminative stimulus effects of morphine in rats after acute or chronic treatment with morphine.

Authors:  Yukun Chen; Marianne Evola; Alice M Young
Journal:  Psychopharmacology (Berl)       Date:  2012-08-04       Impact factor: 4.530

Review 7.  Interactive Mechanisms of Supraspinal Sites of Opioid Analgesic Action: A Festschrift to Dr. Gavril W. Pasternak.

Authors:  Grace C Rossi; Richard J Bodnar
Journal:  Cell Mol Neurobiol       Date:  2020-09-24       Impact factor: 5.046

8.  Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity.

Authors:  Thomas A Munro; Loren M Berry; Ashlee Van't Veer; Cécile Béguin; F Ivy Carroll; Zhiyang Zhao; William A Carlezon; Bruce M Cohen
Journal:  BMC Pharmacol       Date:  2012-05-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.